Arcturus Therapeutics Inc (ARCT) Price to Earnings Ratio

Corporate emblem and logo of Arcturus Therapeutics Inc (ARCT)

The P/E ratio of Arcturus Therapeutics (ARCT) based on net income demonstrates the current market valuation, where the value -2.80 captures the metric level. The scientific management of Arcturus Therapeutics (ARCT) effectively implements mRNA technologies through global alliances. Production cycles and trials are fully delegated to external CRO/CMO contractors. A stable cash flow is maintained through licensing royalties from corporate behemoths, which strengthens the operating balance.

Arcturus Corp (ARCT) Price to Earnings Ratio: for the period 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Arcturus Pharma (ARCT)

- price and consensus price forecast:
Stock Price arcturusrx.com|ARCT - Price Target Chart
- market capitalization details:
Market Value Arcturus Therapeutics Holdings Inc.|ARCT - Enterprise Value
- book capitalization information:
Net Assets per Share Arcturus Therapeutics|ARCT - Company Net Assets|Market Capitalization to Net Assets arcturusrx.com|ARCT - Company Total Assets
- debt and solvency information:
Debt to Capital Arcturus Therapeutics|ARCT - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Arcturus Corp|ARCT - Company Total Debt|Debt to Net Assets Ratio Arcturus Therapeutics Holdings Inc.|ARCT - Company Long-Term Debt|Current Liabilities Arcturus Therapeutics|Intermediate Coverage Ratio arcturusrx.com
- earnings and market multiples details:
ARCT - Net Profit|Projected Future Earnings Arcturus Therapeutics|ARCT - Price to Earnings Ratio|Future Price to Earnings Multiple Arcturus Therapeutics Inc|ARCT - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Arcturus Therapeutics Holdings Inc.|ARCT - Operating profit EBITDA|Net earnings per share (EPS TTM) Arcturus Therapeutics|ARCT - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth arcturusrx.com|ARCT - Earnings per share growth in current year|Expected earnings per share trend next year Arcturus Therapeutics
- issuer revenue and sales details:
ARCT - Revenue and Sales Volume|Company Future Sales Volume arcturusrx.com|ARCT - Market Cap to Revenue|Price to Expected Revenue Ratio Arcturus Therapeutics Holdings Inc.
General company analysis:arcturusrx.com - ARCT
Original product of arcturusrx.com

The specific nature of Arcturus Therapeutics (ARCT), which focuses on R&D while fully outsourcing production and trials, makes the company's P/E dynamics a key indicator of market expectations regarding its intellectual property. The ratio of market capitalization to net income measures the cost of one dollar of earnings, revealing hidden asset manipulations and assessing the fundamental purity of quotes to determine the actual quality of the business.

Analysis of competing companies

P/E Multiple vrtx.com|Price to Earnings Ratio Alnylam (ALNY)|Price to Earnings Ratio INSM (Insmed Inc.)|P/E Multiple UTHR (United Therapeutics Corp.)|Business Payback Period BioMarin Corp (BMRN)|BBIO: Price to Earnings Ratio|Market Cap to Net Income BGM|COGT: P/E Multiple|Market Cap to Earnings Xeris Biopharma Holdings, Inc. (XERS)|KROS (Keros Pharma) - P/E Multiple|Price to Earnings Multiple ETON (Eton Corp)|Price to Earnings Ratio KMDA (Kamada Ltd.)|FULC (fulcrumtx.com) - Company Value to Net Income|Price to Earnings Ratio Abeona Therapeutics Inc. ABEO|MREO (Mereo BioPharma Group) - Market Cap to Net Income|Protalix - P/E Multiple|Company Value to Net Income PLRX (Pliant Therapeutics)|APLT: P/E Multiple|aileronrx.com (RNTX) - P/E Multiple|Price to Earnings Ratio Gelteq Ltd|AYTU: Company Value to Net Income|Price to Earnings Ratio Chemomab Therapeutics (CMMB)|Price to Earnings Ratio srxhealth.com SRXH|P/E Multiple PLRZ (Polyrizon)|P/E Multiple Aeterna Zentaris Inc AEZS|Cyclo Therapeutics, Inc. - P/E Multiple|INZY - P/E Multiple|Reneo Pharma (RPHM) - Price to Earnings Ratio|COSCIENS Bio - Company Value to Net Income